{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:31:32Z","timestamp":1794493892941,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QC209"],"award-info":[{"award-number":["ZR2022QC209"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH202"],"award-info":[{"award-number":["ZR2023QH202"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32501303"],"award-info":[{"award-number":["32501303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303251"],"award-info":[{"award-number":["82303251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000525"],"award-info":[{"award-number":["82000525"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873883"],"award-info":[{"award-number":["81873883"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The abnormal formation of the membrane attack complex (MAC) is intrinsically linked to a range of acute and chronic immune diseases. The insertion of complement C9 into the membrane is the final step and kinetic bottleneck of MAC formation. However, research on blocking the MAC formation of C9 is currently limited. Given its broad, flat, and polar functional interface, complement C9 is a challenging target for rational design. Here, we utilize deep learning-based methods for protein scaffold generation, sequence design, and complex structure prediction to de novo design mini-protein inhibitors that specifically block the membrane insertion of soluble complement C9. The binding affinity of the mini-protein inhibitor is further optimized to 700 pM via partial diffusion. Design accuracy and binding specificity are verified through X-ray crystallography and biochemical studies. An in vivo acute hemolysis inhibition assay reveals that the C9 mini-protein inhibitors remain effective against hemolysis even 8\u2009minutes after complement activation, outperforming the complement C5 inhibitor eculizumab. The de novo designed C9 mini-protein inhibitors can offer an optional therapeutic approach for the prevention and treatment of acute or chronic immune diseases associated with abnormal complement activation.<\/jats:p>","DOI":"10.1038\/s41467-026-70667-x","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:54:22Z","timestamp":1773280462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Design of miniprotein inhibitors targeting complement C9 to block membrane attack complex assembly"],"prefix":"10.1038","volume":"17","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-5825","authenticated-orcid":false,"given":"Ningning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-2086","authenticated-orcid":false,"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-3648","authenticated-orcid":false,"given":"Longxing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaocheng","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6375-7703","authenticated-orcid":false,"given":"Shujuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-6280","authenticated-orcid":false,"given":"Bowen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"70667_CR1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood.V78.3.820.820","volume":"78","author":"LA Wilcox","year":"1991","unstructured":"Wilcox, L. A., Ezzell, J. L., Bernshaw, N. J. & Parker, C. J. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood 78, 820\u2013829 (1991).","journal-title":"Blood"},{"key":"70667_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1172\/JCI114311","volume":"84","author":"MH Holguin","year":"1989","unstructured":"Holguin, M. H., Wilcox, L. A., Bernshaw, N. J., Rosse, W. F. & Parker, C. J. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.  J. Clin. Investig. 84, 1387\u20131394 (1989).","journal-title":"J. Clin. Investig."},{"key":"70667_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau, E. et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 97, 1287\u20131296 (2020).","journal-title":"Kidney Int."},{"key":"70667_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","volume":"12","author":"E T\u00fcz\u00fcn","year":"2013","unstructured":"T\u00fcz\u00fcn, E. & Christadoss, P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun. Rev. 12, 904\u2013911 (2013).","journal-title":"Autoimmun. Rev."},{"key":"70667_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ITT.S261414","volume":"9","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza, R., Vanoli, F., Frangiamore, R. & Cavalcante, P. Complement inhibition for the treatment of myasthenia gravis. ImmunoTargets Ther. 9, 317\u2013331 (2020).","journal-title":"ImmunoTargets Ther."},{"key":"70667_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock, S. J. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.  N. Engl. J. Med. 381, 614\u2013625 (2019).","journal-title":"N. Engl. J. Med."},{"key":"70667_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock, S. J. et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann. Neurol. 93, 1053\u20131068 (2023).","journal-title":"Ann. Neurol."},{"key":"70667_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10588","volume":"7","author":"NV Dudkina","year":"2016","unstructured":"Dudkina, N. V. et al. Structure of the poly-C9 component of the complement membrane attack complex. Nat. Commun. 7, 10588 (2016).","journal-title":"Nat. Commun."},{"key":"70667_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07653-5","volume":"9","author":"A Menny","year":"2018","unstructured":"Menny, A. et al. CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nat. Commun. 9, 5316 (2018).","journal-title":"Nat. Commun."},{"key":"70667_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26366-w","volume":"12","author":"A Menny","year":"2021","unstructured":"Menny, A. et al. Structural basis of soluble membrane attack complex packaging for clearance. Nat. Commun. 12, 6086 (2021).","journal-title":"Nat. Commun."},{"key":"70667_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36441-z","volume":"14","author":"EC Couves","year":"2023","unstructured":"Couves, E. C. et al. Structural basis for membrane attack complex inhibition by CD59. Nat. Commun. 14, 890 (2023).","journal-title":"Nat. Commun."},{"key":"70667_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nsmb.3196","volume":"23","author":"MM Jore","year":"2016","unstructured":"Jore, M. M. et al. Structural basis for therapeutic inhibition of complement C5. Nat. Struct. Mol. Biol. 23, 378\u2013386 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"70667_CR13","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.  N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"70667_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.  N. Engl. J. Med. 355, 1233\u20131243 (2006).","journal-title":"N. Engl. J. Med."},{"key":"70667_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon, S. Eculizumab: A review in generalized myasthenia gravis. Drugs 78, 367\u2013376 (2018).","journal-title":"Drugs"},{"key":"70667_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton, J. E. Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs 80, 719\u2013727 (2020).","journal-title":"Drugs"},{"key":"70667_CR17","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky, R. A. et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111, 1840\u20131847 (2008).","journal-title":"Blood"},{"key":"70667_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock, S. J. et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.  Lancet Neurol. 12, 554\u2013562 (2013).","journal-title":"Lancet Neurol."},{"key":"70667_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","volume":"65","author":"M Le Quintrec","year":"2015","unstructured":"Le Quintrec, M. et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am. J. Kidney Dis. J. Natl. Kidney Found. 65, 484\u2013489 (2015).","journal-title":"Am. J. Kidney Dis. J. Natl. Kidney Found."},{"key":"70667_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A. & Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256\u20131264 (2007).","journal-title":"Nat. Biotechnol."},{"key":"70667_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","volume":"129","author":"MJ Harder","year":"2017","unstructured":"Harder, M. J. et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 129, 970\u2013980 (2017).","journal-title":"Blood"},{"key":"70667_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura, J. et al. Genetic variants in C5 and poor response to eculizumab.  N. Engl. J. Med. 370, 632\u2013639 (2014).","journal-title":"N. Engl. J. Med."},{"key":"70667_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1182\/bloodadvances.2020001690","volume":"4","author":"K Lin","year":"2020","unstructured":"Lin, K. et al. Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes. Blood Adv. 4, 2049\u20132057 (2020).","journal-title":"Blood Adv."},{"key":"70667_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968206","volume":"13","author":"E Lekova","year":"2022","unstructured":"Lekova, E. et al. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Front. Immunol. 13, 968206 (2022).","journal-title":"Front. Immunol."},{"key":"70667_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10058-7","volume":"10","author":"ES Parsons","year":"2019","unstructured":"Parsons, E. S. et al. Single-molecule kinetics of pore assembly by the membrane attack complex. Nat. Commun. 10, 2066 (2019).","journal-title":"Nat. Commun."},{"key":"70667_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill, A., DeZern, A. E., Kinoshita, T. & Brodsky, R. A. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Prim. 3, 17028 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"70667_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.tmrv.2019.09.007","volume":"33","author":"LT Roumenina","year":"2019","unstructured":"Roumenina, L. T., Bartolucci, P. & Pirenne, F. The role of complement in post-transfusion hemolysis and hyperhemolysis reaction. Transfus. Med. Rev. 33, 225\u2013230 (2019).","journal-title":"Transfus. Med. Rev."},{"key":"70667_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMra1802338","volume":"381","author":"SR Panch","year":"2019","unstructured":"Panch, S. R., Montemayor-Garcia, C. & Klein, H. G. Hemolytic transfusion reactions.  N. Engl. J. Med. 381, 150\u2013162 (2019).","journal-title":"N. Engl. J. Med."},{"key":"70667_CR29","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1182\/bloodadvances.2019000897","volume":"3","author":"SA Lau-Braunhut","year":"2019","unstructured":"Lau-Braunhut, S. A. et al. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv. 3, 3575\u20133578 (2019).","journal-title":"Blood Adv."},{"key":"70667_CR30","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","volume":"2","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th, A. et al. Eculizumab in cold agglutinin disease (DECADE): An open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2, 2543\u20132549 (2018).","journal-title":"Blood Adv."},{"key":"70667_CR31","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood.2021014955","volume":"140","author":"A R\u00f6th","year":"2022","unstructured":"R\u00f6th, A. et al. Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial. Blood 140, 980\u2013991 (2022).","journal-title":"Blood"},{"key":"70667_CR32","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","volume":"123","author":"J Shi","year":"2014","unstructured":"Shi, J. et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 123, 4015\u20134022 (2014).","journal-title":"Blood"},{"key":"70667_CR33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0161-5890(92)90129-L","volume":"29","author":"M Hatanaka","year":"1992","unstructured":"Hatanaka, M. et al. Analysis of C5b-8 binding sites in the C9 molecule using monoclonal antibodies: participation of two separate epitopes of C9 in C5b-8 binding. Mol. Immunol. 29, 911\u2013916 (1992).","journal-title":"Mol. Immunol."},{"key":"70667_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71487-z","volume":"14","author":"FM Masson","year":"2024","unstructured":"Masson, F. M. et al. Klebsiella LPS O1-antigen prevents complement-mediated killing by inhibiting C9 polymerization. Sci. Rep. 14, 20701 (2024).","journal-title":"Sci. Rep."},{"key":"70667_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"70667_CR36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.adp1779","volume":"386","author":"M Gl\u00f6gl","year":"2024","unstructured":"Gl\u00f6gl, M. et al. Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists. Science. (N. Y., NY) 386, 1154\u20131161 (2024).","journal-title":"Science. (N. Y., NY)"},{"key":"70667_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","volume":"605","author":"L Cao","year":"2022","unstructured":"Cao, L. et al. Design of protein-binding proteins from the target structure alone. Nature 605, 551\u2013560 (2022).","journal-title":"Nature"},{"key":"70667_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50919-4","volume":"15","author":"B Huang","year":"2024","unstructured":"Huang, B. et al. De novo design of miniprotein antagonists of cytokine storm inducers. Nat. Commun. 15, 7064 (2024).","journal-title":"Nat. Commun."},{"key":"70667_CR39","doi-asserted-by":"crossref","unstructured":"Torres, S. V. et al. De novo designed proteins neutralize lethal snake venom toxins. Nature 639, 225\u2013231 (2025).","DOI":"10.1038\/s41586-024-08393-x"},{"key":"70667_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/science.adl5364","volume":"384","author":"L Lu","year":"2024","unstructured":"Lu, L. et al. De novo design of drug-binding proteins with predictable binding energy and specificity. Science (N. Y., NY) 384, 106\u2013112 (2024).","journal-title":"Science (N. Y., NY)"},{"key":"70667_CR41","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41557-025-01929-2","volume":"17","author":"B Yu","year":"2025","unstructured":"Yu, B. et al. De novo design of light-responsive protein-protein interactions enables reversible formation of protein assemblies. Nat. Chem. 17, 1910\u20131919 (2025).","journal-title":"Nat. Chem."},{"key":"70667_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymeth.2004.03.024","volume":"34","author":"ZS Derewenda","year":"2004","unstructured":"Derewenda, Z. S. The use of recombinant methods and molecular engineering in protein crystallization. Methods (San. Diego, Calif.) 34, 354\u2013363 (2004).","journal-title":"Methods (San. Diego, Calif.)"},{"key":"70667_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41421-018-0009-2","volume":"4","author":"W Yin","year":"2018","unstructured":"Yin, W. et al. Crystal structure of the human 5-HT(1B) serotonin receptor bound to an inverse agonist. Cell Discov. 4, 12 (2018).","journal-title":"Cell Discov."},{"key":"70667_CR44","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41586-025-09429-6","volume":"646","author":"M Pacesa","year":"2025","unstructured":"Pacesa, M. et al. One-shot design of functional protein binders with BindCraft. Nature 646, 483\u2013492 (2025).","journal-title":"Nature"},{"key":"70667_CR45","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3389\/fimmu.2019.01936","volume":"10","author":"C El Sissy","year":"2019","unstructured":"El Sissy, C. et al. Clinical and genetic spectrum of a large cohort with total and sub-total complement deficiencies. Front. Immunol. 10, 1936 (2019).","journal-title":"Front. Immunol."},{"key":"70667_CR46","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/infdis\/jix143","volume":"215","author":"J Rosain","year":"2017","unstructured":"Rosain, J. et al. Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies.  J. Infect. Dis. 215, 1331\u20131338 (2017).","journal-title":"J. Infect. Dis."},{"key":"70667_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599974","volume":"11","author":"JJE Koopman","year":"2020","unstructured":"Koopman, J. J. E., van Essen, M. F., Rennke, H. G., de Vries, A. P. J. & van Kooten, C. Deposition of the membrane attack complex in healthy and diseased human kidneys. Front. Immunol. 11, 599974 (2020).","journal-title":"Front. Immunol."},{"key":"70667_CR48","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","volume":"78","author":"A Armento","year":"2021","unstructured":"Armento, A., Ueffing, M. & Clark, S. J. The complement system in age-related macular degeneration. Cell. Mol. life Sci. 78, 4487\u20134505 (2021).","journal-title":"Cell. Mol. life Sci."},{"key":"70667_CR49","doi-asserted-by":"crossref","unstructured":"Piri, N. & Kaplan, H. J. Role of complement in the onset of age-related macular degeneration. Biomolecules 13, 832 (2023).","DOI":"10.3390\/biom13050832"},{"key":"70667_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.seminhematol.2018.05.014","volume":"55","author":"R Notaro","year":"2018","unstructured":"Notaro, R. & Sica, M. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications. Semin. Hematol. 55, 130\u2013135 (2018).","journal-title":"Semin. Hematol."},{"key":"70667_CR51","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2015-02-625871","volume":"126","author":"Z Lin","year":"2015","unstructured":"Lin, Z. et al. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 126, 891\u2013894 (2015).","journal-title":"Blood"},{"key":"70667_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05717-0","volume":"9","author":"BA Spicer","year":"2018","unstructured":"Spicer, B. A. et al. The first transmembrane region of complement component-9 acts as a brake on its self-assembly. Nat. Commun. 9, 3266 (2018).","journal-title":"Nat. Commun."},{"key":"70667_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D., Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. Sect. D., Biol. Crystallogr."},{"key":"70667_CR54","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. Sect. D., Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. Sect. D., Biol. Crystallogr."},{"key":"70667_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci.: A Publ. Protein Soc. 27, 14\u201325 (2018).","journal-title":"Protein Sci.: A Publ. Protein Soc."},{"key":"70667_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38328-5","volume":"14","author":"NR Bennett","year":"2023","unstructured":"Bennett, N. R. et al. Improving de novo protein binder design with deep learning. Nat. Commun. 14, 2625 (2023).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70667-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70667-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70667-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:02:36Z","timestamp":1777334556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70667-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70667"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70667-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.Y., S.L., M.L., X.F., and N.W. are coinventors on a patent application for invention (applicant: Shandong Second Medical University; application number: CN202511704580.7; status: under substantive examination) that incorporates the usage of mini-protein binders P9 and P57 in hemolysis inhibition. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3827"}}